选择性环氧化酶-2抑制剂对卵巢癌细胞抑制作用的体内体外研究  

Inhibitory effects of selective COX-2 inhibitor on the growth of ovarian cancers in vitro and in vivo

作　　者：辛兵[1] 王敏[1] 

机构地区：[1]中国医科大学附属盛京医院,辽宁沈阳110004

出　　处：《现代肿瘤医学》2015年第18期2561-2565,共5页Journal of Modern Oncology

摘　　要：目的:研究选择性环氧化酶-2抑制剂美洛昔康在体内体外对卵巢癌生长侵袭的抑制作用。方法:使用2种卵巢癌细胞株,研究不同浓度的美洛昔康对于卵巢癌细胞增殖的抑制作用。利用移植卵巢癌细胞株小鼠模型,研究美洛昔康对小鼠背部皮下移植瘤生长以及肿瘤中VEGF表达、微血管密度以及细胞凋亡的影响,并将之与顺铂的作用相比较。结果:在体外实验中,美洛昔康对2种卵巢癌细胞的增殖均有抑制作用,且呈剂量依赖性。体内实验证明美洛昔康明显抑制小鼠皮下移植瘤的生长,其抑制率为30.79%(P<0.0001)。各组肿瘤组织中VEGF的表达经半定量测定分别为:每高倍视野对照组5.17±0.52、、顺铂组4.32±0.73及美洛昔康组4.81±0.58。与对照组相比,美洛昔康饲养的小鼠肿瘤中VEGF的表达受到明显抑制(P<0.0001)并伴随微血管密度的明显减低。TUNEL法对肿瘤组织中凋亡细胞计数,结果分别为:对照组12.8±1.3、顺铂组11.5±1.8及美洛昔康组23.3±2.7。与对照组比较,美洛昔康饲养的小鼠肿瘤中,细胞凋亡的数量明显增多(P<0.001)。美洛昔康的抗肿瘤效果在某些方面优于顺铂。结论:美洛昔康在体内体外实验中表现出抗卵巢肿瘤生长和侵袭的作用。选择性环氧化酶-2抑制剂或许可以作为潜在的新型抗卵巢癌药物应用于临床。Objective：To investigate the inhibitory effects of meloxicam,a selective COX -2 inhibitor on growth of epithelial ovarian cancer （EOC）in vitro and in viv0．Methods：To investigate whether meloxicam inhibit the prolifer-ation of human ovarian cancer cell lines and evaluated the ability of meloxicam on tumor growth,apoptosis,vascular endothelial growth factor （VEGF）level,microvessel density（MVD）and angiogenesis of xenografted tumors derived from EOC cells and compared the antitumor ability to cisplatin.Results：Meloxicam significantly decreased prolifera-tion of both two cell lines in a dose -dependent manner.Meloxicam suppressed the growth of OVCAR -3 tumors,the inhibition rate was 30.79% for meloxicam （P 〈0.0001）.The staining score of VEGF was 4.81 ±0.58 for meloxi-cam and significantly decreased in the meloxicam as compared to control （P 〈0.0001）.The incidence of apoptotic cells was significantly higher in the meloxicam than in the control （P 〈0.001）.Conclusion：Meloxicam significantly inhibits growth and invasiveness of EOC in vitro and in viv0．The inhibitory effect of meloxicam suggests a potential to lead a novel therapeutic strategy against EOC.

关 键 词：选择性环氧化酶-2抑制剂 卵巢癌 体内实验 体外实验 

分 类 号：R73-361[医药卫生—肿瘤] R737.1[医药卫生—临床医学]